69 87

Cited 6 times in

Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis

 Chang-Hoon Kim  ;  Jin Kook Kim  ;  Hyun Jun Kim  ;  Jin Hee Cho  ;  Jung-Soo Kim  ;  Yong-Dae Kim  ;  Heung-Man Lee  ;  Sung Wan Kim  ;  Kyu-Sup Cho  ;  Sang Hag Lee  ;  Chae-Seo Rhee  ;  Hun-Jong Dhong  ;  Ki-Sang Rha  ;  Joo-Heon Yoon 
 ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, Vol.7(2) : 158-166, 2015 
Journal Title
Issue Date
Allergic rhinitis ; ciclesonide ; levocetirizine
PURPOSE: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). METHODS: Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 µg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). RESULTS: Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination. CONCLUSIONS: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.
Files in This Item:
T201506035.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chang Hoon(김창훈) ORCID logo https://orcid.org/0000-0003-1238-6396
Yoon, Joo Heon(윤주헌)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.